Associated Genetic Biomarkers
ALK G1202del is a predictive biomarker for use of crizotinib in patients.
Non-small cell lung carcinoma has the most therapies targeted against ALK G1202del or its related pathways .
Non-Small Cell Lung Carcinoma -
|Biomarker Criteria:||Predicted Response: Acquired Resistance|
|Clinical Setting(s): Metastatic (MCG)|
|Note: Secondary mutations associated with ALK TKI therapy may arise in the kinase domain, leading to acquired resistance.|
ALK G1202del serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains ALK G1202del as an inclusion criterion, 1 is phase 2 (1 open).
Trials with ALK G1202del in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma .
Crizotinib and lorlatinib are the most frequent therapies in trials with ALK G1202del as an inclusion criteria .
Significance of ALK G1202del in Diseases
Non-Small Cell Lung Carcinoma +
ALK is altered in 5.44% of non-small cell lung carcinoma patients .
ALK G1202del is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK G1202del and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.